Nordic Capital announces agreement to sell ArisGlobal to Dassault Systèmes, following its transformation into a scaled and AI-enabled life sciences platform

Nordic Capital has announced a definitive agreement to sell ArisGlobal, a prominent software provider in the life sciences sector, to Dassault Systèmes for an undisclosed amount. This transaction marks a full exit for Nordic Capital, which has successfully partnered with ArisGlobal since 2019 to enhance its technological capabilities and market position. The deal is subject to customary regulatory approvals and is anticipated to close in the second half of 2026.

Founded in 1989 and headquartered in Waltham, Massachusetts, ArisGlobal has evolved into a leading AI-enabled, cloud-native platform that serves over 200 clients, including major pharmaceutical and biotechnology firms, contract research organizations (CROs), and government health authorities. Its flagship LifeSphere® platform integrates regulatory, safety, and quality software solutions, enabling organizations to manage complex regulatory submissions and pharmacovigilance workflows efficiently. The platform's advanced AI capabilities streamline processes, reducing manual intervention and expediting safety case management.

The strategic rationale behind the acquisition lies in the growing demand for sophisticated software solutions within the life sciences industry. As regulatory complexities increase and data volumes rise, companies require robust systems that can adapt to these challenges. The partnership with Nordic Capital allowed ArisGlobal to modernize its technology and broaden its product offerings, including the launch of NavaX, a generative AI solution designed to automate safety case processing. This innovation has positioned ArisGlobal as a leader in the application of AI in drug safety, enhancing its competitive edge in a rapidly evolving market.

The combination of ArisGlobal's expertise in AI-enabled safety and regulatory software with Dassault Systèmes' extensive capabilities in research, clinical development, and manufacturing creates a compelling strategic fit. This acquisition is expected to leverage Dassault's global scale and customer reach, providing ArisGlobal with the resources necessary to further innovate and expand its offerings. The transaction reflects a broader trend in the life sciences sector, where companies increasingly seek integrated solutions that can streamline compliance workflows and enhance operational efficiency.

As the life sciences industry continues to face mounting regulatory pressures and the need for advanced technological solutions, the acquisition of ArisGlobal by Dassault Systèmes underscores the importance of investing in innovative software capabilities. This transaction is likely to drive further consolidation in the sector, as companies recognize the value of comprehensive, AI-driven platforms that can effectively manage regulatory risks and accelerate drug development processes. The outlook for ArisGlobal, under Dassault's ownership, appears promising as it embarks on its next phase of growth and innovation in a dynamic market landscape.